180
Participants
Start Date
August 21, 2025
Primary Completion Date
August 30, 2030
Study Completion Date
August 30, 2033
Taletrectinib
Intervention Label: Taletrectinib Intervention Name: Taletrectinib Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level (s): 400 mg QD Route of Administration: Oral Use: Experimental IMP and NIMP/AxMP : IMP Former Name(s) or Alias(es): AB-106.
Placebo
Intervention Label: Placebo Intervention Name: Placebo Type: Drug Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level(s): 400 mg QD Route of Administration: Oral Use: Placebo Comparator IMP and NIMP/AxMP: IMP Former Name(s) or Alias(es): Placebo
RECRUITING
Virginia Cancer Specialists, Fairfax
RECRUITING
Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South, Austin
RECRUITING
Dana Farber Cancer Institute, Boston
Lead Sponsor
Nuvation Bio Inc.
INDUSTRY